Literature DB >> 8652836

Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2.

C Y Ho1, B Otterud, R D Legare, T Varvil, R Saxena, D B DeHart, S E Kohler, J C Aster, S B Dowton, F P Li, M Leppert, D G Gilliland.   

Abstract

Linkage analysis was performed on a large pedigree with an autosomal dominant platelet disorder and a striking propensity in affected family members to develop hematologic malignancy, predominantly acute myelogenous leukemia. We report the linkage of the autosomal dominant platelet disorder to markers on chromosome 21q22. Four genetic markers completely cosegregate with the trait and yield maximum logarithm of difference scores ranging from 4.9 to 10.5 (theta = .001). Two flanking markers, D21S1265 and D21S167, define a critical region for the disease locus of 15.2 centimorgan. Further analysis of this locus may identify a gene product that affects platelet production and function and contributes to the molecular evolution of hematologic malignancy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8652836

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  The gene for May-Hegglin anomaly localizes to a <1-Mb region on chromosome 22q12.3-13.1.

Authors:  J A Martignetti; K E Heath; J Harris; N Bizzaro; A Savoia; C L Balduini; R J Desnick
Journal:  Am J Hum Genet       Date:  2000-03-17       Impact factor: 11.025

2.  AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.

Authors:  Wei Wang; Sven Schwemmers; Elizabeth O Hexner; Heike L Pahl
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

3.  Regulation of platelet myosin light chain (MYL9) by RUNX1: implications for thrombocytopenia and platelet dysfunction in RUNX1 haplodeficiency.

Authors:  Gauthami Jalagadugula; Guangfen Mao; Gurpreet Kaur; Lawrence E Goldfinger; Danny N Dhanasekaran; A Koneti Rao
Journal:  Blood       Date:  2010-09-27       Impact factor: 22.113

4.  Anticipation in familial leukemia.

Authors:  M Horwitz; E L Goode; G P Jarvik
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

Review 5.  Role of RUNX1 in hematological malignancies.

Authors:  Raman Sood; Yasuhiko Kamikubo; Paul Liu
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

Review 6.  Molecular pathophysiology of myelodysplastic syndromes.

Authors:  R Coleman Lindsley; Benjamin L Ebert
Journal:  Annu Rev Pathol       Date:  2012-08-28       Impact factor: 23.472

7.  Runx1 dose-dependently regulates endochondral ossification during skeletal development and fracture healing.

Authors:  Do Y Soung; Laleh Talebian; Christina J Matheny; Rosa Guzzo; Maren E Speck; Jay R Lieberman; Nancy A Speck; Hicham Drissi
Journal:  J Bone Miner Res       Date:  2012-07       Impact factor: 6.741

8.  Hereditary leukemia due to rare RUNX1c splice variant (L472X) presents with eczematous phenotype.

Authors:  A Sorrell; C Espenschied; W Wang; J Weitzel; S Chu; P Parker; S Saldivar; R Bhatia
Journal:  Int J Clin Med       Date:  2012-12-01

Review 9.  Myeloid neoplasms with germ line RUNX1 mutation.

Authors:  Yoshihiro Hayashi; Yuka Harada; Gang Huang; Hironori Harada
Journal:  Int J Hematol       Date:  2017-05-22       Impact factor: 2.490

Review 10.  Familial leukemias.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2015-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.